For research use only
| Cat No. | ABC-X0133C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Host Cell | HEK293 |
| Source Organ | Kidney |
| Disease | Normal |
| Storage | Liquid Nitrogen |
The Xpress™ human CXCR6 overexpression cell line features stably integrated HEK293 cells, suitable for research on tumor progression and validation.
Xpress™ Human CXCR6 over-expressing cell line is a genetically engineered model derived from selected HEK293 parental cell line based on customers’ requirement. Human CXCR6 overexpression cell line is generated by stable integration of exogenous human CXCR6 into HEK293 host cells using our optimized transduction of lentiviral vectors. Overexpression clone is validated at gene level by qRT-PCR.
Target
CXCR6 (C-X-C motif chemokine receptor 6) is a G protein-coupled receptor involved in chemokine signaling, particularly binding its ligand CXCL16. It plays a role in immune cell trafficking, tumor infiltration, and inflammatory responses. CXCR6 is expressed in T cells, NK cells, and is implicated in cancers such as melanoma, prostate, and liver cancer.AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0133C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO₂ |
| Source Organ | Kidney |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | HEK293 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
The CXCR6 HEK293 Overexpression Cell Line is a valuable tool for investigating chemokine signaling pathways and immune cell recruitment in the tumor microenvironment. It supports research on CXCR6-mediated tumor progression and immunotherapy target validation.